El-Sayed advocates for youth gender-affirming care amid scrutiny of his medical licensing
Abdul El-Sayed, a Democratic candidate for the U.S. Senate representing Michigan, recently articulated a strong defense of gender-affirming care for minors, asserting that treatment decisions should rest solely with medical professionals and patients, or their parents. His comments, made during a campaign rally at Michigan State University, underscored a contentious debate surrounding government intervention in healthcare choices, particularly concerning youth.
El-Sayed, who has consistently highlighted his background as a physician throughout his campaign, maintained that individuals who have completed extensive medical training are the ultimate authorities on patient care. This position comes as his own medical credentials have drawn attention, with reports indicating a lack of active medical licenses in both Michigan and New York.
Candidate emphasizes medical expertise and patient autonomy
During his address, El-Sayed passionately defended the expertise of the medical community, stating that doctors undergo rigorous training, including medical school, residency, and often fellowships, alongside demanding examinations, to provide comprehensive healthcare. He argued that these highly trained professionals are best equipped to determine necessary treatments.
He articulated a clear boundary for government involvement, suggesting that the state should not dictate healthcare decisions, even under a universal healthcare system like the “Medicare for All” plan he champions. According to El-Sayed, the fundamental principle should be that treatment plans are formulated in the clinical setting, involving only the patient—or their parents if they are under 18—and their healthcare provider.
The candidate drew a parallel with the “Right to Try Act,” a bipartisan initiative supported by conservatives, which allows terminally ill patients access to experimental treatments. He implied that this legislation demonstrates a shared belief across the political spectrum in limiting government interference in individual health choices, urging that this standard be consistently applied to all medical decisions.
Scrutiny over El-Sayed’s professional medical standing
Despite frequently positioning himself as a “physician” in his campaign, El-Sayed’s medical licensing history has become a point of contention. Prior reports revealed that he has not held a medical license in either Michigan or New York, raising questions about the implications of this detail for his public messaging and political platform.
His campaign materials have often highlighted his medical background, with El-Sayed suggesting he would be the first doctor to serve as a Democratic senator in half a century if elected. This emphasis on his medical qualifications has, however, brought increased scrutiny to the specifics of his professional standing within the medical field. Requests for comment from El-Sayed’s office regarding his medical credentials have reportedly gone unanswered.
National and international shifts in youth gender-affirming care
El-Sayed’s remarks coincide with significant governmental actions in the United States aimed at regulating access to gender-affirming procedures for minors. The Trump administration has actively pursued measures to restrict such treatments, which include hormone therapy and surgical interventions for individuals seeking to align their physical appearance with their gender identity.
Recent developments include agreements reached by the Justice Department with several prominent medical institutions to cease gender-affirming procedures for children. These facilities include:
- Mount Sinai
- Texas Children’s Hospital
- Cleveland Clinic Foundation
- Connecticut Children’s Hospital
Furthermore, the Centers for Medicare & Medicaid Services (CMS) has moved to end funding for certain gender-affirming procedures for children, classifying them as “experimental” treatments. This national trend reflects a broader reevaluation of these practices, both domestically and internationally.
Debate intensifies over efficacy and ethical guidelines
The medical and ethical landscape surrounding gender-affirming care for minors is complex and continually evolving. Research into the long-term efficacy and potential side effects of “cross-sex” hormones and puberty blockers for treating gender dysphoria in young individuals remains limited, contributing to ongoing debate among healthcare professionals and policymakers.
Adding another layer of complexity, the World Professional Association for Transgender Health (WPATH), an organization whose guidelines are frequently referenced by leading medical associations, is currently facing legal challenges. The Federal Trade Commission (FTC) has initiated a lawsuit against WPATH, alleging that its guidelines may have misled parents regarding the “medical consensus and medical necessity, as well as the safety and effectiveness” of gender-affirming procedures. The FTC’s complaint specifically points to WPATH’s alleged failure to adequately disclose potential side effects associated with some treatments, such as incontinence, erectile pain, mood disturbances, and pelvic or vaginal pain resulting from “cross-sex” hormones.
Internationally, countries with socialized medicine systems have also begun implementing restrictions on gender-affirming care for minors. In March, England’s National Health Service (NHS) paused the use of “cross-sex” hormones for 16 and 17-year-olds, citing “really weak” research supporting their use. This decision followed an existing ban on such hormones for children under the age of 16, highlighting a global trend toward more cautious approaches to these treatments for younger populations.
